Hantong Medical Completes RMB 100 Million Pre-A Funding Round to Advance Ultrasound-Based RDN Commercialization

VCBeat has learned that Hantong Medical recently announced the completion of its Pre-A financing round, amounting to hundreds of millions of yuan. This round of financing was led byFortune Capital, JF CapitalandPudong Angel Venture Capital Fundco-invested by, among others,Changhai CapitalServing as the financial advisor for this transaction. The funds raised will be used to accelerate the clinical development and industrialization of Hantong Medical’s ultrasound-guided renal denervation (RDN) product, while focusing on the research and development layout of innovative products in the field of interventional ultrasound.

Hantong Medical, established in 2022, is a platform-based innovative enterprise in the pan-vascular field with interventional ultrasound as its core technology. The company has successively received honors such as “Shanghai Specialized and Sophisticated SME,” “National Technology-Based SME,” and “Pudong New Area ‘Mingzhu Entrepreneurial Leading Talent.’” The oversubscription of this financing round demonstrates investors’ high recognition of Hantong Medical’s leading industrialization layout in the field of interventional ultrasound, as well as their solid confidence in the company’s future development.

Dr. Zhao Wanjin, Founder and CEO of Hantong Medical“We are deeply honored to have earned the trust and strong support of both new and existing shareholders. After more than two years of dedicated efforts, the company’s proprietary second-generation ultrasound renal denervation (RDN) product has rapidly advanced to the clinical stage. The excellent clinical outcomes from dozens of completed cases have fully validated the product’s safety and efficacy. Our accumulated expertise and innovations in interventional ultrasound have gained consistent recognition from physicians and patients alike. This financing will accelerate the R&D and clinical progression of our pipeline products. Hantong Medical will focus on the pan-vascular interventional ultrasound sector, integrating innovative technologies with clinical needs to develop differentiated and unique leading products that address critical clinical challenges and benefit a broad patient population.”

Fortune Capital“It has been stated: ‘Renal denervation (RDN) has emerged as a research hotspot in the field of hypertension both domestically and internationally in recent years. In China, where there are over 250 million patients with hypertension, long-term reliance solely on pharmacological therapy for blood pressure control has resulted in a blood pressure target attainment rate of less than 20%. The RDN sector holds substantial clinical value and market demand. The core team at Hantong Medical is among the earliest in China to engage in the field of interventional ultrasound, boasting profound technical reserves and full-stack development capabilities. This has enabled the efficient development of next-generation innovative uRDN products and their rapid advancement into the clinical stage. Fortune Capital highly recognizes the irreplaceable and unique value of interventional ultrasound technology in the pan-vascular domain, as well as its vast market potential. We look forward to partnering with Hantong Medical to achieve steady and long-term progress, jointly contributing to the healthcare industry.’”

Wang Keshu, Partner at Changhai Capital“He stated, ‘Ultrasound-based renal denervation (RDN) is one of the few single-product tracks in the cardiovascular field that still holds immense potential for growth, with mounting clinical evidence validating the superiority of the ultrasound approach. Hantong not only demonstrates distinctive features, innovation, and significantly superior efficacy in its flagship product, but also possesses the capability to develop additional related products leveraging its ultrasound platform technology in the future. The team boasts top-tier technical expertise, execution capabilities, and financial management skills. Following this round of financing, the company will accelerate the rapid development of domestically produced RDN solutions more efficiently and swiftly, thereby benefiting a larger number of patients.’”

Hantong Medical is committed to becoming a globally leading enterprise in cardiovascular interventional ultrasound diagnosis and treatment. The founding team consists of pioneering senior industry professionals who are trailblazers in China’s interventional ultrasound field. Core technical personnel hail from prestigious universities such as Shanghai Jiao Tong University, Fudan University, Beijing Institute of Technology, and Donghua University. They possess over ten years of experience at leading domestic and international medical device companies, established China’s first vascular interventional ultrasound product platform, and have developed high-end active medical devices including intravascular ultrasound catheters and endoscopic ultrasound catheters. They have spearheaded the development of multiple products that were selected for the Innovative Medical Device program and received regulatory approval. The team has repeatedly received support from the National Science and Technology Major Project during the 13th Five-Year Plan period and won first prize in the China Medical Device Innovation and Entrepreneurship Competition, demonstrating exceptional capabilities in technological development and product commercialization.

Fortune Capital is one of the most influential venture capital firms in China. With its outstanding performance, Fortune Capital has consistently ranked among the top in evaluations by authoritative institutions such as the China Venture Capital Association, Zero2IPO Group, CVSource, and Financing China. It has been listed among Zero2IPO’s “Top 50 Best Venture Capital Firms in China” for 23 consecutive years, ranking first in 2012 and 2015, and maintaining a position among the top three domestic venture capital firms over the past decade. Furthermore, in the evaluations of private equity fund managers investing insurance funds conducted by the Insurance Asset Management Association of China in 2020, 2021, 2022, and 2023, Fortune Capital was rated as a Class A institution with high scores for four consecutive years.

Jifeng Capital is a premier venture capital firm dedicated to the healthcare and medical sectors. The name “Jifeng” embodies the philosophy of “achieving success through incremental progress, and reaching new heights with far-reaching vision.” We are committed to helping entrepreneurs build their businesses in a sustainable, cyclical manner. By empowering companies with comprehensive value-added services and a global perspective, we drive innovation and aim to deliver long-term value to the development of the healthcare industry and human health. Staying true to our entrepreneurial roots, we consistently uphold professionalism and diligence, serving founders as strategic partners over the long term.

Pudong Angel Fund, established in 2023, has a total fund size of RMB 2 billion, with an initial close of RMB 1 billion. It focuses on “early-stage, small-scale, and hard-tech” investments, continuously strengthening Pudong’s role as a source of technological innovation and a hub for industrial clusters. The fund prioritizes the “four new tracks” and “five future industries,” emphasizing the synergy between investment and incubation to drive high-quality development of Pudong’s technology and industry sectors. By providing robust capital support for early-stage sci-tech innovation projects, the fund helps Pudong New Area build a more comprehensive innovation ecosystem, empowering technological innovation and high-quality industrial development in Pudong.

Changhai Capital is a financial advisory firm specializing in the life sciences and high-end manufacturing sectors. It provides companies with in-depth, customized financing strategies and comprehensive services, offering long-term financial advisory support to numerous niche market leaders across various industries. The company has established long-term collaborations with many leading universities in China, accumulating extensive experience in early-stage incubation and the commercialization of scientific and technological achievements. Meanwhile, it has built extensive connections with multinational corporations (MNCs), US dollar funds, and overseas resource partners, assisting Chinese enterprises in their comprehensive global expansion, including overseas business development and capital operations.